🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Excited for the randomized study studying shorter(14) day course of Ven for older AML patients.May mean less toxicity & preserved efficacy based on data by Keith W Pratz MD .Kudos The Leukemia & Lymphoma Society for championing! #BeatAML #leusm lls.org/news/leukemia-…The James Joshua Zeidner MD Yazan Madanat, MD

Beat AML investigator Dr. Josh Zeidner will present early data from our BAML-16-001-S17 study. Revumenib in combo with Ven/Aza in ND AML w/ NPM1m or KMT2a arr. AML. Joshua Zeidner MD The Leukemia & Lymphoma Society #beataml #LLS

After airplane delays, I’ve reunited with my #BeatAML team at #ASH23 #LLS

Attending “Achieving Next Level” care in AML at #ASH23 Majority of Doctors feel comfortable administering 14-21 days of Venetoclax in ND AML for cycle 1! More reason for the The Leukemia & Lymphoma Society #BeatAML clinical trial, #OptiAML !

#ASH23 PeerView’s Achieving “Next-Level” Care in AML session mentioning #BeatAML Revuminab/Ven/Aza trial in Newly Diagnosed AML. First peak of data Monday morning at Syndax ‘s investor meeting. The Leukemia & Lymphoma Society

“We still have an unmet need in treatment. We still need to invest time & resources” - Ashley Yocum, LLS Executive Lead for the BeatAML Master Trial. 🕰️ Learn how this trial is meeting these unmet needs & the progress it’s made at poster #1535 in the exhibit hall at 5:30PT #ASH23

Hey #ASH23. Come to poster 1535 and learn about #OptiAML from #BeatAML from Dr. Uma Borate: Associate Professor Uma Borate! lls. 14 days of Ven bs 28 in ND AML

WATCH: Ashley Yocum, PhD, discusses the Beat AML Trial of biomarker-based treatments in acute myeloid leukemia. #AML | The Leukemia & Lymphoma Society targetedonc.com/view/yocum-dis…

Check out #BeatAML. Thanks Targeted Oncology 👍

A leader in Ohio State Hematology care and research, Dr. Uma Borate (Dr. Uma Borate: Associate Professor) shares her thoughts on the importance of support for girls and women as they prepare for, enter and work in #STEM fields. #InternationalDayOfWomenAndGirlsInScience

What is —-? Thanks for the shout out Jeopardy! #LLS #BeatAML

We are delighted to share that Dr. Ashley Yocum, Executive Research Strategy Lead, Beat AML Master Trail, The Leukemia and Lymphoma Society will be sharing her expertise as a speaker at the London Biotechnology Show. Register today at bit.ly/3PjLKSx #lbs #lbs24

Come see our Beat AML innovative trial posters ! see details 👇🏾 #ASH24

Pickleball at ASH! Science is fun! #ASH24 #beataml #lls

That’s a wrap for a fantastic menin inhibitor session at #ASH24 featuring revumenib, enzomenib, Bleximenib, ziftomenib & combinations with SOC therapies . Wonderful informative presentations by Joshua Zeidner MD , Dr. Aldoss, Amer Zeidan MBBS,MHS ‏عامر زيدان Ghayas Issa & Emma Seattle. See my detailed

#NewsAlert: We’re thrilled to announce that Syndax will be presenting clinical data showcasing revumenib and axatilimab at the European Hematology Association (EHA) Congress, including an oral presentation highlighting updated results from the frontline BEAT AML trial of

#NewsAlert: Today, we announced that data from the BEAT AML trial in combination with ven/aza in newly diagnosed mNPM1 and KMT2Ar #AML patients were published in the Journal of Clinical Oncology and simultaneously presented in an oral session at the 30th @EHA_hematology Annual